Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 53.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 243,628 shares of the biotechnology company's stock after acquiring an additional 85,082 shares during the period. JPMorgan Chase & Co. owned approximately 1.15% of Enanta Pharmaceuticals worth $2,524,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ENTA. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $122,000. Barclays PLC grew its position in Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company's stock valued at $285,000 after buying an additional 20,478 shares during the period. Geode Capital Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company's stock worth $4,946,000 after acquiring an additional 14,575 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company's stock valued at $588,000 after acquiring an additional 18,003 shares during the period. Finally, American Century Companies Inc. raised its holdings in Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock worth $362,000 after purchasing an additional 7,287 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA traded down $0.13 during trading hours on Tuesday, hitting $5.12. 441,080 shares of the company were exchanged, compared to its average volume of 720,582. Enanta Pharmaceuticals, Inc. has a 52-week low of $4.71 and a 52-week high of $17.80. The stock has a market capitalization of $108.49 million, a price-to-earnings ratio of -0.93 and a beta of 0.56. The company's 50 day moving average price is $7.12 and its 200-day moving average price is $10.65.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.20). The company had revenue of $14.60 million for the quarter, compared to analysts' expectations of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business's quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.33) EPS. On average, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ENTA. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Robert W. Baird reduced their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, November 26th. Finally, HC Wainwright lowered their target price on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, December 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $17.25.

Insider Buying and Selling at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares of the company's stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.64% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.